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Ⅰ．Introduction
 Natural killer （NK） T cells have been 
identified as a novel lymphoid lineage distinct 
from conventional T cells and NK cells. NK T 
cells express both T cell receptor （TCR） and 
NK1 antigen, a member of the family of NKR-P1 
natural killer cell receptors［1-4］. NK T cells 
are CD4－ CD8－ double negative （DN） or CD4 
positive T cells in mice［1-4］and DN T cells in 
human［5-8］. These NK T cells have unusual 
features in comparison with conventional T 
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SUMMARY
Natural Killer （NK） T cells regulate immune responses including autoimmunity and are 
selectively decreased in autoimmune disease. We investigated the regulatory role of CD4－ 
CD8－ double-negative （DN） invariant TCR Vα24JαQ T cells, a human counterpart of murine 
NK T cells, in the development of chronic graft-versus-host disease （GVHD） that resemble to 
autoimmune disease in clinical features. For this purpose, we monitored frequencies of invari-
ant Vα24JαQ DN T cells in PBL from 8 bone marrow transplantation （BMT） patients, 4 of 
whom developed chronic GVHD. Invariant Vα24＋ DN T cells were recovered at 3 mo. after 
BMT as a dominated population of DN Vα24 T cells. However, the recovery of these cells 
was delayed compared with that of conventional T cells. Furthermore, we found that invari-
ant Vα24JαQ DN T cells were not detected at the onset of chronic GVHD and that invariant 
Vα24JαQ DN T cells were again found after successful treatment for chronic GVHD with 
prednisolone. These results indicate that the selective reduction of invariant Vα24JαQ DN T 
cells is related to the disease progression of chronic GVHD, suggesting that the NK T cells 
may regulate the development of chronic GVHD.
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cells and may play an important role in the 
regulation of some immune responses. First, 
NK T cells use highly restricted TCR. Murine 
NK T cells use an invariant TCR Vα14Jα281 
that preferentially pairs with Vβ8.2, Vβ7, and 
Vβ2［9,10］. Human NK T cells are DN T cells 
bearing invariant Vα24JαQ that has a high 
homology with murine Vα14Jα281 chain in both 
the amino acid and nucleotide sequences［5-8］
and are paired with Vβ11 and Vβ13 which also 
have a high homology with murine Vβ8 and 
Vβ7［7,8］. This highly restricted TCR on NK 
T cells recognizes a monomorphic MHC class 
I-like molecule CD1, rather than polymorphic 
MHC molecules［11-15］. Second, NK T cells can 
promptly produce large amounts of interleukin-4 
（IL-4） and interferon-γ （IFN-γ） by stimulation 
with anti-CD3 antibody［15-20］. In addition, NK 
T cells have cytolytic activities in Fas/FasL－
［21］and perforin/granzymes- mediated manners
［22］. Third, NK T cells have been suggested 
to regulate the autoimmune process［23,24］. NK 
T cells are decreased in correlation with the 
disease activity in autoimmune diseases in mice
［23-25］. Furthermore, selective reduction of 
invariant Vα24JαQ DN T cells （human NK T 
cells） has been reported in human autoimmune 
diseases including systemic sclerosis, diabetes 
and systemic lupus erythematosus （SLE）
［26-28］. Thus, NK T cells are importantly 
involved in regulation of immune reactions 
including immune diseases. 
 Chronic graft-versus-host disease （GVHD） 
is immune disease caused by anti-host immune 
responses and is the most frequent delayed 
complication after bone marrow transplantation
［29,30］. Clinical features of chronic GVHD were 
similar to those in autoimmune diseases［30-32］. 
Chronic GVHD causes scleroderma similar to 
systemic sclerosis. Chronic GVHD also develops 
liver injury resembling to autoimmune hepatitis 
or primary biliary cirrhosis. Keratoconjunctivitis 
and sialoadenitis like in Sjogren syndrome 
are developed in chronic GVHD. In addition, 
esophageal strictures, intestinal involvement 
and pulmonary insufficiency similar to that 
in systemic sc leros is were observed in 
chronic GVHD. Furthermore, autoantibodies 
were detected in sera from chronic GVHD 
patients. Thus, clinical features similar to 
autoimmune diseases and the presence of 
autoantibodies in chronic GVHD suggest that 
immunological mechanisms similar to that in 
autoimmune diseases play important roles in 
the development of chronic GVHD. However, 
it remains to be clarified the regulatory role of 
invariant Vα24JαQ DN T cells （human NK T 
cells） in the development of chronic GVHD.
 Therefore, to elucidate this issue, we 
analyzed the frequency of invariant Vα24JαQ 
DN T cells in recipients with BMT every month 
after BMT, and at the onset of chronic GVHD 
and after prednisolone therapy. Our results 
showed that invariant Vα24JαQ DN T cells 
were recovered by 3 mo. after BMT. Moreover, 
our results indicate that invariant Vα24JαQ 
DN T cells are closely related to the disease 
progression of chronic GVHD, as indicated 
by the selective reduction of DN Vα24JαQ T 
cells at the onset of and during chronic GVHD 
and the recovery of those cells after successful 
prednisolone therapy, suggesting that NK T 
cells might be involved in the development of 
chronic GVHD.
Ⅱ．Materials and Methods
Patients
 Fourteen adult recipients enrolled in this 
study gave informed consent in accordance 
with the Declaration of Helsinki, and an ethics 
committee at site approved the protocol. 
Recipients were diagnosed as leukemia, 
lymphoma or aplastic anemia and were given 
allogenic BMT at Chiba university hospital in 
1997. All adult recipients were studied at every 
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1 mo. after BMT and at the onset of chronic 
GVHD. Six recipients dropped out from this 
study because of BMT failure and of relapse. 
We evaluated data from eight recipients （3 
males and 5 females, aged 19 to 34） included 
in this study who had not dropped out from 
this study. Our data from Chiba university 
BMT recipients （not published） shows chronic 
GVHD develops 40-60% after BMT and in this 
study four recipients were free from chronic 
GVHD and four recipients were not. Eight adult 
recipients who were diagnosed as leukemia, 
lymphoma or aplastic anemia and were given 
allogenic BMT （3 males and 5 females, aged 
19 to 34） were studied at every 1 mo. after 
BMT and at the onset of chronic GVHD. All 
recipient were prepared with cyclophosphamide 
（60 mg/kg for 2 days） followed by total-body 
irradiation （12 Gy） before BMT. After total-
body irradiation, 3x108 cells/kg of bone marrow 
cells from unrelated donors were infused 
intravenously. G-CSF was used during the 
period of granulocytopenia for 7 to 14 days. To 
prevent development of acute GVHD, 100 to 
150 mg/day cyclosporine was used for 28 days 
and methotrexate was given for four times （15 
mg/㎡ on day 1, 10 mg/㎡ on day 3, 6, 11 after 
BMT）. 
 Acu t e  GVHD was  d i agnosed  ba sed 
upon clinical findings and histopahological 
confirmation when possible and graded as 
1994 Consensus Conference［33］. Six of eight 
patients （case 3-8） developed acute GVHD 
by 1mo after BMT. One patient （case 3） had 
developed grade III GVHD involving skin and 
intestine. Other five patients developed grade I 
GVHD involving skin in five patients and liver 
in one patient. All acute GVHD patients were 
treated with prednisolone （2 mg/kg/day） for 
14 days following reduction of dosage and their 
symptoms were improved. No symptoms and 
abnormal findings were observed at 3 mo after 
BMT. 
 Chronic GVHD was diagnosed based 
upon clinical findings and histopahological 
confirmation when possible and was graded 
as criteria by Shulmann et al［34］. Four out of 
eight recipients （case 1-4） developed chronic 
GVHD. One patient （case 2） developed limited 
GVHD with skin involvement and three patients 
developed extensive type GVHD involving skin 
and liver （case 1 and 4） and skin and lung 
（case 3）. All patients with chronic GVHD were 
treated with prednisolone at the initial dose 
of 2 mg/kg/day for 2 to 6 weeks, and then 
the dosage was gradually reduced. At 6 mo. 
after BMT, all patients were improved and no 
symptoms and abnormal findings were observed 
after 2 mo. prednisolone therapy.  Four healthy 
subjects, sex and age matched, were also 
examined as controls. 
Flow Cytometry
 Peripheral blood lymphocytes （PBL） were 
isolated from 50 ml of heparinized peripheral 
venous blood of eight BMT recipients and five 
healthy subjects by Ficoll-Paque （Pharmacia 
Fine Chemicals, Uppsala, Sweden） density 
gradient centrifugation.
 Cells （1 x 106） were stained with fluorescence- 
or biotin-conjugated antibodies in phosphate-
buffered saline containing 1 % fetal calf serum 
for 30 min at 4 ℃. The following fluorescein 
isothiocyanate （FITC）-, phycoerythrin （PE）-, or 
biotin-conjugated monoclonal antibodies （mAb） 
were used: CD4 （Leu-3a）, CD8 （Leu-2a）, TCR 
αβ （Becton Dickinson, Mountain View, CA） 
and TCR Vα24 （Cosmo Bio Co., Tokyo, Japan）. 
Cells stained with biotinylated mAb were then 
incubated with streptoavidin-PE or -Tricolor 
（Caltag, San Francisco, CA）. Stained cells 
were resuspended in phosphate-buffered saline 
containing 1 % fetal calf serum and analyzed by 
FACScan （Becton Dickinson） using Cell Quest 
program. 
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Purification of CD4－ CD8－ Double-negative T 
Cells
 CD4－ CD8－ double-negative （DN） TCR αβ 
T cells were sorted from PBL of BMT recipients 
and healthy subjects by FACStar （Becton 
Dickinson） using anti-CD4 plus anti-CD8 mAb. 
The yields of DN T cells were approximately 1 
x 105.
Detection of invariant Vα24JαQ gene by PCR
 Total RNA （0.1-1 μg） was prepared from 
sorted DN T cells by the method of acid 
guanidinium thiocyanate/phenol/chloroform 
extraction using Isogen solution （Nippon 
Gene Co., Tokyo, Japan）. The first strand 
complementary DNA （cDNA） was then 
synthesized from 0.1-1 μg of total RNA in 20 μl 
of reaction buffer containing oligo-dT primer 
using avian myeloblastosis virus reverse 
transcriptase. The reaction mixture was 
incubated at 25 ℃ for 10 min and then at 42 ℃ 
for 60 min.
 To amplify invariant Vα24JαQ gene, we 
used nested polymerase chain reaction （PCR） 
method. cDNA from DN T cells were first 
amplified by PCR using primers for Vα24 
（5-AAGCAAGATACTGGGAGAGGT-3） and Cα 
（5-ATGTCTAGCACAGTTTTGTCTGTG-3）. 
The denaturing step was done at 95 ℃ for 1.5 
min, the annealing step at 60 ℃ for 1 min, and 
the extension step at 72 ℃ for 1 min, for 25 
cycles on a DNA thermal cycler （Perkin-Elmer 
Corp., Norwalk, CT）. PCR products were then 
amplified by polymerase chain reaction （PCR） 
using primers for invariant Vα24JαQ （5-AGC
GACAGAGGCTCAACCCT-3） and Cα （5-GG
TGAATAGGCAGACAGACTT-3） at 95 ℃ for 
1.5 min, the annealing step at 62 ℃ for 1 min, 
and the extension step at 72 ℃ for 1 min, for 
25 cycles. For detection of Vα24 gene products, 
first PCR products were then amplified using 
inner Vα24 primer （5-CTCAGCGATTCAGC
CTCCTAC-3） and inner Cα primer （5-GGTG
AATAGGCAGACAGACTT-3） for 25 cycles. 
The PCR products were loaded at 2% agarose 
gel and detected by ethidium bromide （Nippon 
Gene, Co. Ltd.）. This nested PCR method 
allowed us to detect one invariant Vα24JαQ T 
cells in 1-5 x 105 cells. 
Determination of frequency of Vα24JαQ gene 
in Vα24 clones by colony PCR 
 TCR Vα24 cDNAs from DN T cells were 
amplified by PCR using primers for Vα24 with 
an EcoRI restriction site （5’-CGAATTCCTCAG
CGATTCAGCCTCCTAC-3’） and Cα （5’-CGAA
TTCGGTGAATAGGCAGACAGACTT-3’）. The 
denaturing step was done at 95 ℃ for 1.5 min, 
the annealing step at 60 ℃ for 1 min, and the 
extension step at 72 ℃ for 1 min, for 30 cycles 
on a DNA thermal cycler. PCR products were 
purified by phenol extraction, precipitated with 
ethanol, and digested with excess amounts of 
EcoRI. The DNA fragments with expected sizes 
of the cDNAs were enriched by preparative 
low-melting-point agarose gel electrophoresis. 
The recovered DNA fragments were ligated to 
M13mp19 plasmids obtained by EcoRI digestion. 
Phages were grown on TG-1 Escherichia 
coli cells and recombinant phage DNA was 
purified for colony PCR. DNA from each colony 
was amplified using primers for invariant 
Vα24JαQ and Cα and those for Vα24 and Cα 
for detection for invariant Vα24JαQ and Vα24 
genes, respectively as mentioned above. To 
confirm the results by colony PCR, some clones 
including positive and negative for Vα24JαQ 
gene by colony PCR were sequenced by the dye 
primer method using an automated sequencer 
（Applied Biosystems）. The results of sequence 
analysis were consistent with those by colony 
PCR.
Data Analysis
 Data are summarized as mean ± SD. The 
statistical analysis of the results was performed 
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by the unpaired and paired t-test. P values ＜0.05 
were considered significant.
Ⅲ．Results
Recovery of invariant Vα24JαQ DN T cells 
after BMT
 To determine whether NK T cells were 
recovered after BMT, we analyzed invariant 
Vα24JαQ DN T cells in PBL from 8 BMT 
recipients every month after BMT. For this 
purpose, we used nested PCR method to 
detect the invariant Vα24JαQ gene in which 
Vα24 genes are amplified in 1st PCR and then 
invariant JαQ gene was expanded in second 
PCR. This method could detect one Vα24JαQ 
bearing cell in 1-5 x 105 cells （data nit shown）. 
 The invariant Vα24JαQ gene was detected 
in 3 out of 8 BMT recipients 1 month after BMT 
（Fig. 1A）. All recipients showed the invariant 
Vα24JαQ gene in DN lymphocytes at 3 mo. 
after BMT （Fig. 1B）. Thus, NK T cells were 
recovered by 3 month after BMT.
 In healthy controls, invariant Vα24JαQ T 
cell is a dominant population in DN Vα24 T cells
［5-8］and the frequencies of invariant JαQVα24 
T cells in DN Vα24 T cells were 50-100% （mean 
± sd; 84.1 ± 16.3%） in our study. To determine 
whether recovered invariant Vα24JαQ T cells 
are major population in DN Vα24 T cells, we 
examined the frequencies of invariant Vα24JαQ 
gene in Va24 clones in peripheral blood DN T 
cells of BMT recipients. Invariant JαQ gene 
was dominant in Vα24 clones in DN T cells of 
all BMT recipients at a high frequency （5/16 
to 16/16, mean ± SD: 84 ± 16%） （Table 2）. 
Thus, recovered invariant Vα24JαQ DN T cells 
are a major population in DN Vα24 T cells as 
observed in healthy controls.
 We then estimated absolute numbers 
of invariant Vα24JαQ DN T cells based on 
lymphocytes number, percentage of DN Vα24 
T cells and frequencies of invariant Vα24JαQ 
clones among Vα24 clones in DN T cells. The 
percentage of recovered cell numbers to control 
cell numbers was smaller in invariant Vα24JαQ 
DN T cells than in conventional T cells. At 3 
month after BMT, lymphocyte number, T cell 
number, and DN T cells in BMT recipients 
were smaller than those in healthy controls 
and were about 50%, 30%, and 25% of healthy 
controls, respectively （Table 2）. Cell numbers 
of DN Vα24 T cell and invariant Vα24JαQ DN 
T cell was about 6% and 5% of healthy controls, 
respectively （Table 2）. Thus, recovery of NK 
T cells after BMT was impaired and delayed 
compared to that of conventional T cells. 
 These results indicate that NK T cells were 
recovered by 3 mo. after BMT and were a 
            Case  1   2   3    4    5    6   7   8     JαQ+  JαQ-
A     Vα24JαQ
Vα24
B Vα24JαQ
Vα24
C     Vα24JαQ
Vα24
D Vα24JαQ
Vα24
Fig. 1　 Expression of invariant Vα24JαQ genes in 
DN T cells in PBL from BMT recipients
　Invariant Vα24JαQ mRNA expression was 
examined by nested PCR in DN T cells from PBL 
of BMT recipients at 1 mo. after BMT （A）, and at 3 
mo. after BMT （B）. 
　Invariant Vα24JαQ mRNA expression was 
examined by nested PCR in DN T cells from PBL of 
BMT recipients at the onset of chronic GVHD （4 mo. 
after BMT） （C）, and after prednisolone therapy for 
GVHD （6 mo. after BMT） （D）. Case 1-4 developed 
chronic GVHD at 4 mo. after BMT. These patients 
were successfully treated with prednisolone （2 mg/
kg for 2-6weeks followed by decrease of dosage） and 
no symptoms and abnormal findings were observed 
at 6 mo. after BMT. 
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major population of DN Vα24 T cells, although 
recovery of NK T cells was delayed compared 
to conventional T cells.
Decrease of invariant Vα24JαQ DN T cells in 
chronic GVHD
 Clinical features of chronic GVHD resemble 
those of autoimmune diseases such as systemic 
sclerosis［30,32,35,36］. In autoimmune diseases 
such as systemic sclerosis, SLE, NK T cells, 
Table 1　Profile of BMT Recipients
Age Sex Disease
aGVHD
（Grade）a）
Response 
to Treatment
for aGVHDb）
cGVHD
（Type）c）
Target organ
Response 
to Treatment
for cGVHDb）
Case 1 19 F AML － ＋（EX） Skin, Liver good
Case 2 25 F ALL － ＋（Lt） Skin good
Case 3 24 M AA ＋（III） good ＋（EX） Skin, Lung good
Case 4 24 M CML ＋（I） good ＋（EX） Skin, Liver good
Case 5 25 M ALL ＋（I） good －
Case 6 34 F NHL ＋（I） good －
Case 7 24 F AML ＋（I） good －
Case 8 23 F AML ＋（I） good －
　a） Grading of acute GVHD （aGVHD） according to 1994 Consensus Conference［33］.
　b）  a GVHD and cGVHD was treated with 2 mg/kg/day of prednisolone for 2-4 weeks followed by gradual 
reduction of the dosage.  Response to the treatment was judged by disappearance of the symptoms and 
normalization of findings at 8 weeks after the initiation of the treatment.
　c） Grading of chronic GVHD （cGVHD） according to criteria by Shulman et al.［34］. Ex extensive type, Lt＝
limited type
　aGVHD＝acute GVHD, cGVHD＝chronic GVHD
Table 2　Frequencies of DN αβ T cells and invariant Va24JaQ DN T cells in PBL at 3 mo. after BMT
Case
Lymph
（/㎣）
CD3 T cell
（/㎣）
DN αβ T cell
（/㎣）
DN Vα24 T cell
（/㎣）
JαQ
/DN Vα24
DN Vα24JαQ 
T cell
（/㎣）
1 1360 1132 25.43 0.204 16/16 0.204
2 192 79 0.71 0.035 14/14 0.035
3 2354 951 0.94 0.400 13/16 0.325
4 496 169 0.69 0.198 14/16 0.174
5 442 305 1.15 0.097 15/16 0.091
6 684 85 0.68 0.157 14/16 0.137
7 858 558 6.09 0.266 8/16 0.133
8 768 359 1.77 0.108 12/16 0.081
mean±s.d. 894±683 455±372 4.68±8.02 0.183±0.114 0.147±0.090
Control
（n＝5） 1825±262* 1391±147* 19.28±1.85** 3.12±0.63** 2.73±0.510**
DN TCR αβ T cells and DN TCR Vα24+ T cells in PBL from healthy subjects and recipients with BMT were 
analyzed by FACS using PE-conjugated anti-CD4 plus anti-CD8 mAb and FITC-conjugated anti-TCR αβ mAb 
or anti-Vα24 mAb. Frequencies of invariant Vα24JαQ DN T cells were calculated by DN TCR Vα24+ T cell 
numbers and frequencies of invariant JαQ clones in DN Vα24 cDNA clones which was detrained by colony 
PCR analysis of Vα24 clones in DN T cells.
PBL＝peripheral blood lymphocytes, DN＝CD4－CD8－ double-negative.
Data are means ± SD. *, **significantly different from the mean value of healthy controls, *P＜0.01, **P＜0.001
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invariant Vα24JαQ NK T cells, were decreased
［26-28］. Therefore, to determine whether DN 
invariant Vα24JαQ T cells were decreased 
in chronic GVHD, we analyzed the invariant 
Vα24JαQ gene in DN lymphocytes by PCR 
method in recipients with chronic GVHD before 
prednisolone therapy. Four patients （case 1-4） 
developed chronic GVHD at 4 months after 
BMT.
 At the onset of chronic GVHD, invariant 
Vα24JαQ DN T cells was decreased. Invariant 
Vα24JαQ gene was detected in DN lymphocytes 
from all recipients at 3 mo. after BMT before 
the onset of chronic GVHD （Fig. 1B）. At 4 mo. 
after BMT when chronic GVHD was developed, 
invariant Vα24JαQ gene was not detected in 
all four patients who developed chronic GVHD 
（Fig. 1C）. In contrast, the invariant Vα24JαQ 
gene was detected in DN lymphocytes from 
BMT recipients who did not develop chronic 
GVHD. In addition, disappearance of invariant 
Vα24JαQ DN T cells was observed during the 
active chronic GVHD. Thus, invariant Vα24JαQ 
DN T cells were disappeared in chronic GVHD.
 We also examined frequencies of invariant 
Vα24JαQ gene in Vα24 clones in cGVHD 
patients and estimated the cell numbers. The 
absolute number of invariant Vα24JαQ DN T 
cells was decreased in all four BMT recipients 
when they developed chronic GVHD （before 
c-GVHD 0.184 ± 0.119/㎣ vs. in c-GVHD 0.011 
± 0.020/㎣ , P＜0.05）, although DN Vα24 T 
cell number did not decreased （before c-GVHD 
0.209 ± 0.150/㎣ vs. in c-GVHD 0.222 ± 
0.121/㎣） （Table 3 and Fig. 2）. In contrast to 
chronic GVHD patients, invariant JαQ gene 
was dominantly detected at high frequencies 
（14/16 to 16/16 or 14/14） in BMT recipients 
who did not develop chronic GVHD at 4 mo. 
after BMT. The absolute number of invariant 
Vα24JαQ was increased in BMT recipients 
without chronic GVHD （3 mo. 0.111 ± 0.029/㎣ 
vs. 4 mo. 0.304 ± 0.141/㎣, P＜0.01） （Table 3, 
Fig. 2）. Thus, invariant Vα24JαQ DN T cells 
are selectively reduced in chronic GVHD and 
no clonal expansion of DN Vα24 T cells bearing 
TCR other than invariant Vα24JαQ gene was 
observed.
Table 3　 Frequencies of Invariant JαQ clones in Vα24 cDNA clones obtained from PBL of BMT Recipients 
at the Onset of Chronic GVHD and after Successful Treatment for Chronic GVHD
Before cGVHD cGVHD After GVHD
Case cGVHD
DN Vα24
（/㎣）
JαQ
/DN Va24
DN Vα24
（/㎣）
JαQ
/DN Va24
DN Vα24
（/㎣）
JαQ
/DN Va24
1 ＋ 0.204 16/16 0.277 0/16 0.056 13/16
2 ＋ 0.035 14/14 0.062 1/16 0.051 16/16
3 ＋ 0.400 13/16 0.343 0/15 0.473 14/14
4 ＋ 0.198 14/16 0.206 1/15 0.178 12/16
0.209±0.150a） 0.222±0.121a） 0.190±0.198a）
5 － 0.097 15/16 0.160 12/12 0.446 13/13
6 － 0.157 14/16 0.490 14/16 0.380 16/16
7 － 0.266 8/16 0.625 14/14 0.486 12/12
8 － 0.108 12/16 0.240 14/14 0.465 10/10
0.157±0.077b） 0.304±0.141b） 0.444±0.045b）  
DN TCR αβ T cells and DN TCR Vα24+ T cells in PBL from healthy subjects and recipients with BMT were 
analyzed by FACS using PE-conjugated anti-CD4 plus anti-CD8 mAb and FITC-conjugated anti-TCR αβ 
mAb or anti-Vα24 mAb.  Frequencies of invariant Vα24JαQ DN T cells were calculated by DN TCR Vα24+ T 
cell numbers and frequencies of invariant JαQ clones in DN Vα24 cDNA clones which was was detrained by 
colony PCR analysis of Vα24 clones in DN T cells. DN＝CD4－CD8－ double-negative.
a）Data are means ± SD of cell numbers of BMT recipients with chronic GVHD.
b）Data are means ± SD of cell numbers of BMT recipients without chronic GVHD.
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Recovery of invariant Vα24JαQ DN T cells 
by prednisolone therapy in chronic GVHD 
patients
 To determine whether Vα24JαQ T cells are 
related to the disease activity of chronic GVHD, 
we then examined invariant Vα24JαQ gene by 
PCR method in DN lymphocytes from the same 
four chronic GVHD patients who were treated 
with prednisolone and chronic GVHD was 
rendered inactive states. 
 In inact ive chronic GVHD, invar iant 
Vα24JαQ gene was again detected in DN 
lymphocytes from all four chronic GVHD 
patients treated with prednisolone （Fig. 1D）. 
Furthermore, colony PCR analysis of Vα24 
clones of DN T cells revealed that invariant 
Vα24JαQ T cells dominated in all four patients 
（Table 3）. In two patients （case 2 and 3）, all 
clones were invariant Vα24JαQ. In other two 
patients （case 1 and 4）, invariant JαQ gene also 
dominated in DN Vα24+ T cells at a frequency 
of 13/16, and 12/16, respectively. The absolute 
number of invariant Vα24JαQ T cells was 
increased after prednisolone therapy in all four 
chronic GVHD patients （before prednisolone 
therapy 0.011 ± 0.020/㎣ vs. after prednisolone 
therapy 0.176 ± 0.202, P＝0.10） （Fig. 2）. Thus, 
invariant DN T cells were reappeared after 
prednisolone therapy and the reduction of these 
invariant Vα24JαQ DN T cells were correlated 
with disease activity of chronic GVHD.
Ⅳ．Discussion
 In this study, we showed that invariant 
Vα24JαQ DN T cells, human NK T cells, were 
recovered by 3 mo. after BMT and that the 
recovery of invariant Vα24JαQ DN T cells was 
delayed compared to that of conventional T 
cells. Moreover, we demonstrated that invariant 
Vα24JαQ DN T cells are related to the disease 
progression of chronic GVHD, as indicated by 
selective reduction of invariant Vα24JαQ T 
cells in chronic GVHD and the recovery of those 
cells after successful prednisolone treatment 
for chronic GVHD, suggesting that NK T cells 
might be involved in the development of chronic 
GVHD.
 Many studies about immune reconstitution 
after BMT have shown that increase of NK cells 
was first found during first 2 mo. after BMT 
and then T cells were gradually increase after 
sharp increase of NK cells and normalization of 
T cell numbers takes 6- 24 mo［37-39］. However, 
the recovery of NK T cells after BMT had been 
unknown. Here, we first demonstrated that NK 
T cells appear by 3 mo. after BMT.
 It is sti l l unknown whether invariant 
Vα24JαQ DN T cells found at 3 mo. after BMT 
were originated from donor or host. In this 
study, we failed to sort invariant Vα24JαQ 
DN T cells to decide the origin, because these 
cells are too small population for sorting at 3 
mo. after BMT. However, we believe that these 
invariant Vα24JαQ T cells were donor origin, 
because 1） Fluorescence in situ hybridization 
（FISH） analysis for sex chromatin and PCR 
analysis for variable number of tandem repeats 
（VNTR） revealed that leukocytes were 100% 
donor origin at 3 mo. after BMT, 2） invariant 
Fig. 2　 Cell number of DN invariant Vα24JαQ T 
cells in BMT recipients with chronic GVHD
　DN invariant Vα24JαQ T cells was assessed in 
four BMT recipients without chronic GVHD （left） 
and with chronic GVHD （right） before the onset of 
chronic GVHD （at 3 mo. after BMT）, at the onset 
of chronic GVHD （at 4 mo. after BMT）, and after 
successful prednisolone therapy for GVHD （at 6 mo. 
after BMT）. 
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Vα24JαQ DN T cells continued to increase 
from 3 mo. after BMT （Fig. 2）. Furthermore, 
invariant Vα24JαQ DN T cells at 3 mo. after 
BMT expressed CD45RA, a naive T cell marker, 
and did not bear CD45RO, a memory T cell 
marker, that are expressed on NK T cells in 
healthy controls even in cord blood cells［40］（our 
unpublished data）, suggesting that those cells 
were immature NK T cells probably originated 
from donor stem cell origin rather than from 
remaining host cells or contaminated donor NK 
T cells. 
 We demonstrated that recover ies of 
invariant Vα24JαQ DN T cells are delayed 
compared with that of conventional T cells. 
CD1d recognition is essential for NK T cell 
development, which is shown by defective NK T 
cells in CD1 deficient mice［12-14］. Since CD1d is 
expressed on dendritic cells［4,15,22］, NK T cells 
development after BMT might occurre after the 
reconstitution of CD1d positive dendritic cells. 
This might explain the delay of reconstitution 
of NK T cells. In addition, NK T cells required 
also IL-7 and IL-15 for their development［41,42］. 
Impaired cytokine microenvironment after 
BMT might also delay the development of NK 
T cells. Moreover, if NK T cells are originated 
from donor stem cell and require thymic 
environment for their development, delayed 
or impaired reconstitution is not surprising, 
because it has been shown that majority of 
recovered conventional T cells are memory T 
cells and that generation of naive T cells from 
stem cells were impaired and takes long time in 
adult BMT recipients［43,44］.
 In this study, we demonstrated selective 
reduction of invariant Vα24JαQ DN T cells in 
chronic GVHD. We previously demonstrated a 
selective reduction of invariant Vα24JαQ DN 
T cells in patients with systemic sclerosis［26］. 
In addition, decrease of NK T cells has been 
reported in autoimmune diseases such as type I 
diabetes［27］. Moreover, we recently found that 
invariant Vα24JαQ DN T cells were decreased 
in active SLE and reappeared after prednisolone 
therapy［28］. Therefore, decrease of invariant 
Vα24JαQ DN T cells in chronic GVHD suggests 
that similar immunological abnormalities exist in 
autoimmune diseases and chronic GVHD as well 
as clinical features.
 Dysregulation of cytokine production has 
been shown in chronic GVHD. In murine 
chronic GVHD, T cells with Th2 type cytokine 
profiles are activated and IL-10 production 
is enhanced［45］. In human chronic GVHD, 
cytokine dysregulation was also observed
［46,47］and serum IL-10 levels were elevated
［48］. Furthermore, IL-10 has been shown to 
down regulate CD1 molecules, critical molecules 
for NK T cells development and activation, on 
monocytes［49］. Therefore, increased production 
of IL-10 in chronic GVHD may account for the 
decrease of DN Vα24JαQ T cells. Indeed, we 
found that the cell growth of DN Vα24JαQ T 
cells from healthy subjects was significantly 
inhibited by the addition of IL-10 into the 
culture （our unpublished data）. Interestingly, 
increased IL-10 production was found in SLE
［50,51］and systemic sclerosis patients［52］in 
whom invariant Vα24JαQ DN T cells were 
selectively decreased, suggesting that cytokine 
dysregulation including IL-10 may be shared 
mechanism for reduction of NK T cells. 
 The pathophysiologic role of NK T cells in 
chronic GVHD is to be elucidated. The roles of 
NK T cells in modulating autoimmune diseases 
have been suggested, of which clinical features 
and immunological abnormalities were similar 
to chronic GVHD. Mieza et al［24］demonstrated 
that in vivo deletion of NK T cells accelerated 
the development of autoimmune disease in lpr 
mice, lupus-prone mice, and the introduction 
of Vα14Jα281 transgene delayed the onset of 
the disease, suggesting that NK T cells play a 
role in regulating auto reactive T cells in the 
autoimmune process. Recently, Ikehara et al
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［53］reported that NK T cells plays an critical 
roles in acceptance of xenograft by cytokine 
independent manner. Thus, NK T cells could 
serve as immunosuppressive regulatory 
cells and could regulate the development of 
immunological diseases including autoimmune 
diseases and chronic GVHD. The loss of NK 
T cells might accelerate the development of 
chronic GVHD.
 The regulatory ro les by NK T ce l ls 
in chronic GVHD might be mediated by 
cytokines produced by NK T cells. NK T cells 
produce large amounts of IL-4 and IFN-γ 
upon stimulation. IL-4 produced by NK T cells 
suppresses the development and effects of Th1 
type cells［54］. It has been shown that IL-4 
producing NK T cells suppressed acute GVHD 
that is mediated by Th1 cells in murine model
［55］. On the contrary, IFN-γ regulates Th2 
cells［56］that contribute to the development of 
chronic GVHD［45-47］. Indeed, we found large 
amounts of IFN-γ production by invariant 
Vα24JαQ DN T cells in healthy controls and 
BMT recipients at 3 mo. after BMT （our 
unpublished data）. Thus, cytokines produced by 
NK T cells might regulate the development of 
chronic GVHD.
 In summary, we have shown that invariant 
Vα24JαQ DN T cells was reconstituted after 
BMT, which was delayed compared with 
conventional T cells and that the selective 
reduction and recovery of invariant Vα24JαQ 
DN T cells is related to the disease progression 
in chronic GVHD. 
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要　　旨
　【目的】マウスNK T細胞は IL-4，IFN-γを産生し，免
疫系の調節細胞と考えられている。この細胞はアロ反
応性を抑制し，GVHDを抑制する細胞である可能性が
指摘されている一方で，GVHDにて細胞傷害活性を発
揮し病態増悪因子であることも報告され，未だGVHD
におけるNK T細胞の果たす役割は明確にされていな
い。本研究ではヒトNK T細胞と考えられるCD4－8－
（DN） Va24 JaQ T細胞（NK T細胞）が慢性GVHD
（cGVHD）の病態と関連する可能性があるか否かを検
討する目的で，骨髄移植（BMT）後の末梢血中のNK 
T細胞が再構築する時期，NK T細胞とcGVHD発症と
の相関について解析を行った。
　【方法】 BMT症例 8例（BMT後cGVHD発症 4例，
非発症例 4例）の末梢血を用いた。cGVHD発症前後で
のNK T細胞の flow cytometry法，RT-PCR法等によ
る量的解析を行った｡
　【結果】BMT症例 8例のNK T細胞は末梢血単核球
中の0.02-0.04%であり健常人と比較し低値であり経時的
に変動は認められなかった。このうちNK T細胞の再
構築をRT-PCR法によりBMT後 1から 3ヶ月に認め
た。cGVHD発症群では発症時にNK T細胞が減少し，
ステロイド治療による症状改善と共にNK T細胞は再
増加した。一方，cGVHD非発症群では全経過において
NK T細胞が検出された。
　【結論】NK T細胞はBMT後 3ヶ月で再構築された。
このNK T細胞はcGVHDの活動性に相関して減少，消
失することからNK T細胞はcGVHDの病態に関与して
いる可能性が示唆された。
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